

# Bio-Medicine

- [Home](#)
- [Biology](#)
- [Medicine](#)
- [Technology](#)
- [Products](#)
- [News](#)
- [Definition](#)
- [I](#)

[Search](#)   [RSS](#)

<b>Navigation Links</b>	
Biology News	
Medicine News	
Biology Products	
Medicine Products	
Biology Definition	
Medicine Definition	
Biology Technology	
Medicine Technology	
Biology Dictionary	
Medicine Dictionary	
<b>Biology Navigation</b>	
AIDS/HIV	▲
Bioinformatics	
Biotechnology	
Biochemistry	
Cancer	
Cell Biology	
Developmental Biology	
Ecology	
Environment	
Evolution	
Food Technology	
Gene	
Genetics	
Genomics	
Health/Medicine	▼
<b>Medical Navigation</b>	
	▲

[HOME](#) >> [MEDICINE](#) >> [TECHNOLOGY](#)   [M](#)

## Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel

Date: 3/17/2009 [[Outline](#)] [[RSS & Subscription](#)]

### [Drug safety recall](#)

Nation's #1 Drug Recall Management Recall Experts for Companies  
[www.ExpertRECALL.com](http://www.ExpertRECALL.com)

### [BenzaClin Topical Gel](#)

Buy BenzaClin Topical Gel from Canada. Low shipping rates  
[www.CanadaDrugSuperstore.com](http://www.CanadaDrugSuperstore.com)

### [AMITIZA® \(lubiprostone\)](#)

Official web site for AMITIZA. Get the product profile and more...  
[www.amitiza.com/HCP](http://www.amitiza.com/HCP)

ALLEGAN, Mich., March 17 /PRNewswire-FirstCall Perrigo Company (Nasdaq: PRGO; TASE) today announced that its partner Cobrek Pharmaceuticals, Inc. has an Abbreviated New Drug Application (ANDA) for Clindamycin Phosphate F 1%, a generic version of (R) Foam 1%. The Company believes that Cobrek is the first to file an ANDA with a Paragraph IV certification against Evoclin(R).

Ads by Google

Evoclin(R) (clindamycin phosphate) Foam 1% is indicated for topical application in the treatment of acne vulgaris, and had sales of approximately \$10 million for the 12 months ended January 2009, as measured by Wolters Kluwer Health.

The ANDA for Clindamycin Phosphate Foam, 1%, which was filed prior to enactment of the Q1 Program Supplemental Funding Act of 2008 (the "Q1 Act"), was timely amended to contain a Paragraph IV Certification in accordance with the Q1 Act. On March 11, 2009, Stiefel filed suit alleging patent infringement in the United States District Court for the District of Delaware against Perrigo and its partner Cobrek. Stiefel also has filed a Citizen Petition with the U.S. Food and Drug Administration ("the FDA") seeking a 30 month stay of Cobrek's ANDA approval imposed. The FDA has not ruled, neither have the courts, regarding whether the Q1 Act entitles Stiefel to a 30 month stay.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This filing reflects our continued investment in new products. We are the manufacturer and developer of this product as well as the exclusive sales and marketer. As always, Perrigo is committed to making quality healthcare more affordable for our customers and drive value for our shareholders."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription drugs.

ADHD
Addiction
Alcohol
Allergy
Alternative Medicine
Alzheimer's Dementia
Anxiety/Stress
Arthritis
Autism
Bacteria
Blood
Bird Flu/Avian Flu
Bones

SOURCE Perrigo Company  
 Copyright © 2009 [PR Newswire](#).  
 All rights reserved

0  
**GOOD**

Page: [1](#) [2](#) [3](#)

***Related medicine technology :***

- [1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solu](#)
- [2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity](#)
- [3. Multiple Myeloma Research Consortium \(MMRC\) Partners with Novartis to Adva Phase II Study of Deacetylase Inhibitor](#)
- [4. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health](#)
- [5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity](#)
- [6. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership](#)
- [7. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Instit](#)
- [8. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insight Support Incentive-Driven Wellness Programs](#)
- [9. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers](#)
- [10. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma Partner Pfizer](#)
- [11. UNICEF Partners With Causes on Facebook to Launch Charity Gift Feature](#)

**[Form a Free Corporation](#)**

Live anywhere and Inc in tax-free NV. Since 1989. 30k corps formed.

**[Money for your Lawsuit](#)**

Get the cash you need now! Apply today. Get approved tomorrow.

Ads by Google

**Post Your Comments: ([View All Comments](#))**

\*Name:

\*Comment:

\*Email: